An effective and safe targeted therapy for treatment of Myasthenia gravis

Reference number 2018-04677
Coordinator TOLERANZIA AB
Funding from Vinnova SEK 500 000
Project duration December 2018 - August 2019
Status Ongoing

Purpose and goal

Myasthenia gravis (MG) is a chronic autoimmune neuromuscular disease with a huge unmet need for new effective and safe therapies as current treatment options are only symptomatic and are accompanied by severe side effects. Toleranzia is developing TOL2, a disease-specific drug for treatment of MG. TOL2 has an extraordinary long-lasting therapeutic effect shown in an animal model of MG and could become the first tolerance-inducing therapy in the market. In the proposed project, we will set up and execute a complete feasibility study to assess the potential of TOL2 to reach the market.

Expected results and effects

The feasibility study will include an in-depth market study to further decipher risks and potential entry barriers due to market acceptance and regulations. Moreover, a careful study to further secure IP as well as a business plan will be developed. The results of this project will provide Toleranzia with the necessary resources to effectively implement a high-quality application within the SME Instrument Phase 2 program.

Planned approach and implementation

The project will have a duration of six months. Based on our current organization, four people will lead the main areas of the project, applying our established project management structure (integrated weekly meetings, web-based system for effective and safe document handling, fluid communication among project members and early detection of issues and risks).

The project description has been provided by the project members themselves and the text has not been examined by our editors.